25Oct/13

[ultimate-photo source="pinterest" uid="PioneerPress" display_link="1 … – Pioneer Press (blog)


Pioneer Press (blog)

[ultimate-photo source=”pinterest” uid=”PioneerPress” display_link=”1
Pioneer Press (blog)
Body Worlds: Cycle of Life: through May 5: The Body Worlds exhibit displays human muscle, sinew, fat, arteries, eyeballs and organs all perfectly preserved as plastic. This newest exhibit …. You’ll see world champion fancy dancer Yazzie perform

and more »

25Oct/13

'High-risk' organs from deceased donors safe when screened with current methods – Science Daily (press release)


Counsel & Heal

‘High-risk’ organs from deceased donors safe when screened with current methods
Science Daily (press release)
Oct. 25, 2013 — Approximately 10% of deceased donor kidneys are considered “high-risk” for infection (HIV, HCV, HBV) and disease transmission according to criteria set by the Centers for Disease Control and Prevention. But new research suggests that 
Some ‘High-Risk’ Kidneys May Be Safe for Organ Transplant: StudyHealthDay

all 4 news articles »

25Oct/13

AbbVie Inc (ABBV): AbbVie's CEO Discusses Q3 2013 Results – Earnings Call … – Seeking Alpha

AbbVie Inc (ABBV): AbbVie’s CEO Discusses Q3 2013 Results – Earnings Call
Seeking Alpha
In addition to assets currently in late-stage such as HCV, daclizumab, elagolix, (inaudible) and elotuzumab were on the cusp of transitioning several additional programs in the Phase 3 development, including but not limited to ABT-199 per CLL and ABT

25Oct/13

What's Behind AbbVie's Rocking Q3 Earnings – DailyFinance


Jutia Group

What’s Behind AbbVie’s Rocking Q3 Earnings
DailyFinance
AbbVie’s partnership with Biogen Idec on daclizumab also looks promising. The drug targets treatment of patients with relapsed or remitting multiple sclerosis. Daclizumab is currently in a late-stage study. AbbVie and Biogen expect that study to wrap
AbbVie Inc (ABBV): AbbVie’s CEO Discusses Q3 2013 Results – Earnings Call Seeking Alpha
AbbVie Reports Third-Quarter 2013 Financial ResultsMarketWatch

all 28 news articles »